Spruce Street Capital »

Dianthus Therapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $35M 355k 97.48

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Dianthus Therapeutics

FMR
BlackRock
RA Capital Management
Wellington Management Company
Fairmount Funds Management
Vanguard Capital Management
Avidity Partners Management
Octagon Capital Advisors
TCG Crossover Management
Citadel Advisors
State Street Corporation
VR Adviser
Fred Alger Management
T. Rowe Price Associates
Polar Capital Holdings

View all funds holding Dianthus Therapeutics